Á lódáil...
Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone
AIMS: A new, long‐acting, subcutaneous (SC) formulation of risperidone (RBP‐7000) has been developed for the treatment of schizophrenia to address issues of non‐adherence associated with oral risperidone treatment. The objective of this work was to establish an exposure‐response relationship between...
Na minha lista:
| Foilsithe in: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
John Wiley and Sons Inc.
2017
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5465337/ https://ncbi.nlm.nih.gov/pubmed/28133766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13246 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|